{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:31:36Z","timestamp":1767839496116,"version":"3.49.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.critrevonc.2011.08.002","type":"journal-article","created":{"date-parts":[[2011,9,8]],"date-time":"2011-09-08T19:38:17Z","timestamp":1315510697000},"page":"370-377","source":"Crossref","is-referenced-by-count":9,"title":["Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: Open questions"],"prefix":"10.1016","volume":"82","author":[{"given":"Peter","family":"Valent","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcnther","family":"Gastl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Geissler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Greil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Hantschel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alois","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner","family":"Linkesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Lion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas L.","family":"Petzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Pittermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Pleyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef","family":"Thaler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2011.08.002_bib0005","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myelogenous leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Eng J Med"},{"key":"10.1016\/j.critrevonc.2011.08.002_bib0010","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/shem.2003.50034","article-title":"Molecular mechanisms of transformation by the BCR-ABL oncogene","volume":"40","author":"Sattler","year":"2003","journal-title":"Semin Hematol"},{"key":"10.1016\/j.critrevonc.2011.08.002_bib0015","doi-asserted-by":"crossref","first-page":"8541","DOI":"10.1038\/sj.onc.1206081","article-title":"Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML","volume":"21","author":"Druker","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2011.08.002_bib0020","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2011.08.002_bib0025","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR\/ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2011.08.002_bib0030","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2011.08.002_bib0035","first-page":"534","article-title":"New tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"90","author":"Martinelli","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2011.08.002_bib0040","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.exphem.2007.01.023","article-title":"Optimizing therapy of chronic myeloid leukemia","volume":"35","author":"Deininger","year":"2007","journal-title":"Exp Hematol"},{"key":"10.1016\/j.critrevonc.2011.08.002_bib0045","first-page":"1244","article-title":"Emerging stem cell concepts for imatinib-resistant CML: implications for the biology, management, and therapy of the disease","volume":"36","author":"Valent","year":"2008","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.critrevonc.2011.08.002_bib0050","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood-2007-04-038943","article-title":"How I treat chronic myeloid leukemia in the imatinib era","volume":"110","author":"Goldman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.08.002_bib0055","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/10428190801896210","article-title":"New therapeutic approaches and prognostic factors in chronic myeloid leukemia","volume":"49","author":"Saglio","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2011.08.002_bib0060","first-page":"S22","article-title":"Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia","volume":"6","author":"Cortes","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.critrevonc.2011.08.002_bib0065","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2011.08.002_bib0070","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccr.2005.01.020","article-title":"AMN107: tightening the grip of imatinib","volume":"7","author":"O\u2019Hare","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2011.08.002_bib0075","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2011.08.002_bib0080","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3109\/10428191003637282","article-title":"Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a \u2018head-to-head comparison\u2019","volume":"51","author":"Rosti","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2011.08.002_bib0085","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1182\/blood-2009-07-232595","article-title":"Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia","volume":"114","author":"Rosti","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.08.002_bib0090","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2011.08.002_bib0095","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1586\/ehm.10.61","article-title":"Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study","volume":"3","author":"Giles","year":"2010","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.critrevonc.2011.08.002_bib0100","doi-asserted-by":"crossref","unstructured":"Rosti G, Castagnetti F, Gugliotta G, Palandri F, Baccarani M. Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase. Crit Rev Oncol Hematol; in press, doi:10.1016\/j.critrevonc.2011.04.002.","DOI":"10.1016\/j.critrevonc.2011.04.002"},{"key":"10.1016\/j.critrevonc.2011.08.002_bib0105","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiling of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal different interaction networks and novel kinase and non-kinase targets","volume":"110","author":"Rix","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2011.08.002_bib0110","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.bbapap.2009.11.008","article-title":"Extended kinase profile and properties of the protein kinase inhibitor nilotinib","volume":"1804","author":"Manley","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.critrevonc.2011.08.002_bib0115","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.leukres.2007.01.024","article-title":"Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib","volume":"31","author":"Breccia","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.critrevonc.2011.08.002_bib0120","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.22037","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML","volume":"86","author":"Aichberger","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.critrevonc.2011.08.002_bib0125","unstructured":"le Coutre P, Rea D, Abruzzese E, et al. Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst; in press."},{"key":"10.1016\/j.critrevonc.2011.08.002_bib0130","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/leu.2008.364","article-title":"The stem cell factor-c-KIT pathway must be inhibited to enable apoptosis induced by BCR-ABL inhibitors in chronic myelogenous leukemia cells","volume":"23","author":"Belloc","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2011.08.002_bib0135","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/onc.2010.494","article-title":"Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors","volume":"30","author":"Pittoni","year":"2010","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.critrevonc.2011.08.002_bib0140","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4049\/jimmunol.162.2.1032","article-title":"The mast cell as site of tissue-type plasminogen activator expression and fibrinolysis","volume":"162","author":"Sillaber","year":"1999","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.critrevonc.2011.08.002_bib0145","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1055\/s-0037-1613084","article-title":"New aspects in thrombosis research: possible role of mast cells as profibrinolytic and antithrombotic cells","volume":"87","author":"Valent","year":"2002","journal-title":"Thromb Haemost"},{"issue":"1\u20133","key":"10.1016\/j.critrevonc.2011.08.002_bib0150","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejphar.2008.10.014","article-title":"Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib","volume":"599","author":"Day","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.critrevonc.2011.08.002_bib0155","unstructured":"DDR1 distribution profile in various cell systems and cell types available at: http:\/\/biogps.gnf.org."},{"issue":"5","key":"10.1016\/j.critrevonc.2011.08.002_bib0160","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0002-9440(10)63716-9","article-title":"Role of discoidin domain receptors 1 and 2 in human smooth muscle cell-mediated collagen remodeling: potential implications in atherosclerosis and lymphangioleiomyomatosis","volume":"164","author":"Ferri","year":"2004","journal-title":"Am J Pathol"},{"issue":"10","key":"10.1016\/j.critrevonc.2011.08.002_bib0165","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1161\/CIRCRESAHA.107.170662","article-title":"Discoidin domain receptor 1 (ddr1) deletion decreases atherosclerosis by accelerating matrix accumulation and reducing inflammation in low-density lipoprotein receptor-deficient mice","volume":"102","author":"Franco","year":"2008","journal-title":"Circ Res"},{"issue":"11","key":"10.1016\/j.critrevonc.2011.08.002_bib0170","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1161\/CIRCRESAHA.109.207357","article-title":"Discoidin domain receptor 1 on bone marrow-derived cells promotes macrophage accumulation during atherogenesis","volume":"105","author":"Franco","year":"2009","journal-title":"Circ Res"},{"issue":"11","key":"10.1016\/j.critrevonc.2011.08.002_bib0175","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1161\/CIRCRESAHA.109.213637","article-title":"Increased cell and matrix accumulation during atherogenesis in mice with vessel wall-specific deletion of discoidin domain receptor 1","volume":"106","author":"Franco","year":"2010","journal-title":"Circ Res"},{"key":"10.1016\/j.critrevonc.2011.08.002_bib0180","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1182\/blood.V116.21.207.207","article-title":"ENESTnd Update: continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2011.08.002_bib0185","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"European LeukemiaNet. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"issue":"35","key":"10.1016\/j.critrevonc.2011.08.002_bib0190","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"European LeukemiaNet. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.critrevonc.2011.08.002_bib0195","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.clinthera.2010.05.003","article-title":"Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib","volume":"32","author":"Stein","year":"2010","journal-title":"Clin Ther"},{"issue":"5","key":"10.1016\/j.critrevonc.2011.08.002_bib0200","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1161\/01.ATV.0000124105.39900.db","article-title":"Imatinib attenuates diabetes-associated atherosclerosis","volume":"24","author":"Lassila","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.critrevonc.2011.08.002_bib0205","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.critrevonc.2010.07.003","article-title":"The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib era","volume":"79","author":"Breccia","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"issue":"24","key":"10.1016\/j.critrevonc.2011.08.002_bib0210","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.4161\/cc.5.24.3573","article-title":"Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia","volume":"5","author":"Barnes","year":"2006","journal-title":"Cell Cycle"},{"issue":"5","key":"10.1016\/j.critrevonc.2011.08.002_bib0215","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2404609","article-title":"Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies","volume":"21","author":"Jiang","year":"2007","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.critrevonc.2011.08.002_bib0220","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.critrevonc.2011.08.002_bib0225","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Intergroupe Fran\u00e7ais des Leuc\u00e9mies My\u00e9lo\u00efdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842811001934?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842811001934?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T09:20:44Z","timestamp":1686302444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842811001934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S1040842811001934"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2011.08.002","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}